Document is current
Any future updates will be listed below
-
Authors
Cox, Robert M. https://orcid.org/0000-0003-0620-1674
Sourimant, Julien https://orcid.org/0000-0002-1660-1666
Toots, Mart
Yoon, Jeong-Joong https://orcid.org/0000-0001-9379-0416
Ikegame, Satoshi
Govindarajan, Mugunthan
Watkinson, Ruth E.
Thibault, Patricia
Makhsous, Negar
Lin, Michelle J.
Marengo, Jose R.
Sticher, Zachary https://orcid.org/0000-0002-7022-1410
Kolykhalov, Alexander A.
Natchus, Michael G.
Greninger, Alexander L.
Lee, Benhur
Plemper, Richard K. https://orcid.org/0000-0003-2034-2107
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI071002, AI071002)
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (HD079327)
- License Information
-
More Information
Article History
Received: 15 November 2019
Accepted: 9 June 2020
First Online: 13 July 2020
Competing interests
: R.M.C., B.L. and R.K.P. are co-inventors on a provisional patent application ‘2-fluoro-6-isoquinolin-5-ylbenzamide, and antiviral uses related thereto’, covering the method of use of GHP-88309 for paramyxovirus disease therapy. This study could affect their personal financial statuses. All other authors declare no competing interests.
